Luteinizing hormone–releasing hormone agonists have replaced estrogens for endocrine treatment of advanced prostate cancer (PC) because of cardiovascular side effects. The published study with the fetal estrogen estetrol (E4) in healthy males shows promise as a safe and effective drug for use in prostate cancer.
On Friday June 8, 2018, the CSO of Pantarhei Carole Verhoeven lectured on the treatment of breast cancer with the fetal estrogen estetrol in a scientific symposium entitled ‘Estrogens and breast cancer’. The other lecture (A lesson in contracts. What can we learn from the discrepant breast cancer findings in the WHI?) was presented by Bob Langer. The symposium was chaired by Wulf Utian.
For more information, please read the abstract: Abstract IMS Treatment of breast cancer with the fetal estrogen estetrol.
On 3 May 2018 the first patient has been randomized in the phase IIA clinical study assessing efficacy and safety of the fetal estrogen estetrol (E4) in prostate cancer patients. The study is a double blind, randomised, placebo-controlled multi-center study in prostate cancer patients treated with an LHRH agonist. In total 60 patients will be enrolled at eight centers in the Netherlands.
The main objectives of this study are to evaluate the additional effect of E4 on testosterone (T) suppression (total T as well as free T) by the LHRH agonist as well as the prevention and treatment of hypoestrogenic side effects due to the concomitant suppression of estrogens.